KalshiBeschikbaarheid controlerenKYC vereistGeverifieerde afwikkelingsgegevensGoed gekalibreerdWaarschuwing datakwaliteitVerouderde gegevens
Gegevens van 27 okt 2026, 11:53 UTC · beleid pm-quality-4
Middenprijs van geselecteerd orderboek
Before Jul 1, 2027 · —
Geselecteerd orderboek laden…
—
Opgeslagen prijs
Before Jul 1, 2027 39%Koploper van 3 uitkomsten
Before Jul 1, 2027 39%Marktkwaliteit
34 / 100
Lage kwaliteit24u volume
€ 4,2
Open interest
US$ 7,7K
Gemiddelde open interestBied / Laat
— / —
Before Jul 1, 2027Spread
—
Marktdata
Bijgewerkt 1 uur geleden
Vertraagd14 mei 26, 02:00 UTC1 jan 27, 04:59 UTC
Grafiek en wijzigingen tonen opgeslagen historische kansen, niet het geselecteerde actuele orderboek.
Trends
Geselecteerde rij: middenprijs van het orderboek. Andere rijen: opgeslagen, mogelijk genormaliseerde referenties; wijzigingen over 24 uur gebruiken opgeslagen historie.
Before Oct 1, 2026Verloren
Voorwaarden van het handelsplatform
Bron: Kalshi
Deze voorwaarden zijn ter informatie; voor gesimuleerd handelen bij CoinRithm gelden eigen regels.
- Vervroegde sluiting:
- Ja
- Afwikkelingstermijn:
- 30m (ter informatie)
Marktdiepte · Before Jul 1, 2027
Geselecteerd orderboek laden…
—
Gerelateerde Markten
Gerelateerde vragen voor context, geen vergelijking van gelijkwaardige contracten.
Will the FDA approve CagriSema?
KalshiWill the FDA approve MDMA for PTSD?
KalshiWill the FDA approve intismeran autogene (V940/mRNA-4157)?
KalshiWill the FDA approve any psychedelic substance for medical use this year?
KalshiWhen will the FDA approve Compass Pathways' COMP360 Psilocybin?
KalshiWill the FDA approve a psychedelic-assisted therapy for a mental disorder by 2027?
Manifold MarketsRegels
If the FDA approves cytisinicline for smoking cessation for marketing before Jul 1, 2027, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
Afwikkeling via:Food and Drug Administration
Regels per uitkomst
- Before Jul 1, 2027
- If the FDA approves cytisinicline for smoking cessation for marketing before Jul 1, 2027, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
- Before Jan 1, 2027
- If the FDA approves cytisinicline for smoking cessation for marketing before Jan 1, 2027, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
- Before Oct 1, 2026
- If the FDA approves cytisinicline for smoking cessation for marketing before Oct 1, 2026, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
